Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective

Clinical and Translational Science

Volumn 11, Issue 1, 2018, Pages 11-20

  Dawkins, Hugh J S ^a   Draghia Akli, Ruxandra ^b,c   Lasko, Paul ^d   Lau, Lilian P L ^e   Jonker, Anneliene H ^e   Cutillo, Christine M ^f   Rath, Ana ^e   Boycott, Kym M ^g   Baynam, Gareth ^h,i   Lochmüller, Hanns ^j   Kaufmann, Petra ^f   Le Cam, Yann ^k   Hivert, Virginie ^k   Austin, Christopher P ^f  

^a DEPARTMENT OF HEALTH   (Australia)

^b EUROPEAN COMMISSION   (Belgium)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e INSERM   (France)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^h KING EDWARD MEMORIAL HOSPITAL   (Australia)

ⁱ Western Australian Register of Developmental Anomalies   (Australia)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k Plateforme Maladies Rares   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ADVOCACY GROUP; DRUG RESEARCH; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL RESEARCH; ORGANIZATIONAL POLICY; PATIENT ADVOCACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RARE DISEASE; REVIEW; ADVISORY COMMITTEE; CLINICAL TRIAL (TOPIC); ECONOMICS; HISTORY; INTERNATIONAL COOPERATION; INTERSECTORAL COLLABORATION; ORGANIZATION AND MANAGEMENT; PREVALENCE; STANDARDS; TRANSLATIONAL RESEARCH;

ADVISORY COMMITTEES; CLINICAL TRIALS AS TOPIC; GUIDELINES AS TOPIC; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL COOPERATION; INTERSECTORAL COLLABORATION; PREVALENCE; RARE DISEASES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85040289394     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12501     Document Type: Review

References (60)

1. Stolk, P., Willemen, M.J. & Leufkens, H.G. Rare essentials: drugs for rare diseases as essential medicines. Bull. World Health Organ. 84, 745–751 (2006).
2. Prevalence and Incidence of Rare Diseases: Bibliographic Data, in Orphanet Report Series, Rare Diseases Collection (eds. Rath, A. & Nguengang-Wakap, S.). http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf (2016) Accessed: 29 May 2017.
3. Tambuyzer, E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat. Rev. Drug Discov. 9, 921–929 (2010).
4. Boycott, K.M. et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am. J. Hum. Genet. 100, 695–705 (2017).
5. Melnikova, I. Rare diseases and orphan drugs. Nat. Rev. Drug Discov. 11, 267–268 (2012).
6. List of Rare Diseases by Orphanet. http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf Accessed 21 July 2017.
7. Molster, C. et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J. Rare Dis. 11, 30 (2016).
8. EURORDIS, The Voice of 12,000 Patients: Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe. (2009) EURORDIS-Rare Diseases Europe.
9. Walker, C.E. et al. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort. Genet. Med. 19, 546–552 (2017).
10. Schieppati, A. et al. Why rare diseases are an important medical and social issue. Lancet 371, 2039–2041 (2008).
11. Tweardy, D.J. & Belmont, J.W. “Personalizing” academic medicine: opportunities and challenges in implementing genomic profiling. Transl. Res. 154, 288–294 (2009).
12. Braun, M.M. et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat. Rev. Drug Discov. 9, 519–522 (2010).
13. Committee for Orphan Medicinal, P. et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat. Rev. Drug Discov. 10, 341–349 (2011).
14. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. https://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm (2004) Accessed: 29 May 2017.
15. Abbott, A. Rare-disease project has global ambitions. Nature 472, 17 (2011).
16. IRDiRC Members. Available from: http://www.irdirc.org/about-us/members/ Accessed: 29 May 2017.
17. Orphanet. Available from: http://www.orpha.net/ Accessed: 29 May 2017.
18. Bellacosa, A. Developmental disease and cancer: biological and clinical overlaps. Am. J. Med. Genet. A. 161A, 2788–2796 (2013).
19. Baynam, G. et al. A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macroencephaly and small thoraces. Am. J. Med. Genet. A 167, 1659–1667 (2015).
20. Austin, C.P. et al. Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin. Trans. Sci. 11, 21–27 (2017).
21. Wagner J.A. & Kroetz D.L. Transforming translation: Impact of Clinical and Translational Science. Clin. Transl. Sci. 9:3–5 (2016). https://doi.org.10.1111/cts.12380
22. List of research projects funded by the European Commission. Available from: http://www.irdirc.org/member-funded-research/research-projects/european-commission-european-union/ Accessed 21 July 2017.
23. Julkowska, D. et al. The importance of international collaboration for rare diseases research-a European perspective. Gene Ther. (2017) [Epub ahead of print].
24. List of research projects funded by the E-Rare Consortium. Available from: http://www.irdirc.org/member-funded-research/research-projects/e-rare-european-union/ Accessed 21 July 2017.
25. Baynam, G. et al. The rare and undiagnosed diseases diagnostic service — application of massively parallel sequencing in a state-wide clinical service. Orphanet J. Rare Dis. 11, 77 (2016).
26. Mariz, S. et al. Worldwide collaboration for orphan drug designation. Nat. Rev. Drug Discov. 15, 440–441 (2016).
27. IRDiRC Policies and Guidelines. Available from: http://www.irdirc.org/reports-guidelines/policies-guidelines/ (2013) Accessed: 29 May 2017.
28. Lochmuller, H. et al. The International Rare Diseases Research Consortium: Policies and Guidelines to Maximize Impact (2017) (submitted for publication).
29. Orphanet — Diagnostic Test. Available from: http://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search.php?lng=EN Accessed 30 June 2017.
30. Orphadata: Free Access Data From Orphanet© Inserm 1997. Available from: http://www.orphadata.org Accessed 30 June 2017.
31. Baynam, G. The need for genetic studies of Indegenous Australians. Med. J. Aust. 196, 313 (2012).
32. Hansen, M. et al. Prevalence of microencephaly in an Australian population-based birth defects register, 1980–2015. Med. J. Aust. 206, 351–356 (2017).
33. Recommendations of the IRDiRC Therapies Scientific Committee to implement IRDiRC Policy 2013 and aim of new 200 therapies by 2020. Available from: http://www.irdirc.org/reports-guidelines/policies-guidelines/tsc-recommendations/ Accessed: 29 May 2017.
34. Philippakis, A.A. et al. The Matchmaker Exchange: a platform for rare disease gene discovery. Hum. Mutat. 36, 915–921 (2015).
35. Global Alliance for, G. and Health, GENOMICS. A federated ecosystem for sharing genomic, clinical data. Science 352, 1278–1280 (2016).
36. Automatable Discovery and Access Matrix. Available from: https://genomicsandhealth.org/work-products-demonstration-projects/automatable-discovery-and-access-matrix Accessed: 29 May 2017.
37. Privacy-Preserving Record Linkage. Available from: http://www.irdirc.org/activities/current-activities/privacy-preserving-record-linkage/ Accessed: 29 May 2017.
38. International Consortium of Human Phenotype Terminologies. Available from: http://www.irdirc.org/activities/current-activities/ichpt/ Accessed: 29 May 2017.
39. Patient-Centered Outcome Measures in the Field of Rare Diseases (eds. Sabino, G. et al.) http://www.irdirc.org/activities/current-activities/tf-pcom/ (2016) Accessed: 29 May 2017.
40. Small Population Clinical Trials: Challenges in the Field of Rare Diseases (eds. Jonker, A.H. et al.). http://www.irdirc.org/activities/current-activities/tf-spct/ (2016) Accessed: 29 May 2017.
41. Data Mining and Repurposing. Available from: http://www.irdirc.org/activities/current-activities/data-mining-repurposing/ Accessed: 29 May 2017.
42. Lochmuller, H. et al. ‘IRDiRC Recognized Resources’: a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases. Eur. J. Hum. Genet. 25, 162–165 (2017).
43. Global Genomic Medicine Collaborative (G2MC). Available from: http://www.nationalacademies.org/hmd/Activities/Research/GenomicBasedResearch/Innovation-Collaboratives/Global_Genomic_Medicine_Collaborative.aspx Accessed: 29 May 2017.
44. Thompson, R. et al. RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J. Gen. Intern. Med. 29 (Suppl 3), S780-7 (2014).
45. Bushby, K. et al. Collaborating to bring new therapies to the patient–the TREAT-NMD model. Acta Myol. 28, 12–15 (2009).
46. Taruscio, D. et al. RARE-Bestpractices: a platform for sharing best practice for the management of rare diseases. Rare Dis. Orphan Drugs 1, 5–8 (2014).
47. RD-Action. Available from: http://www.rd-action.eu Accessed: 29 May 2017.
48. European Reference Networks. Available from: http://ec.europa.eu/health/ern/ Accessed: 29 May 2017.
49. Krischer, J.P. et al. The Rare Diseases Clinical Research Network's organization and approach to observational research and health outcomes research. J. Gen. Intern. Med. 29 (Suppl 3), S739–744 (2014).
50. Taruscio, D. et al. Undiagnosed Diseases Network International (UDNI): White paper for global actions to meet patient needs. Mol. Genet. Metab. 116, 223–225 (2015).
51. Rath, A. et al. Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users. Hum. Mutat. 33, 803–808 (2012).
52. Ayme, S., Bellet, B. & Rath, A. Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding. Orphanet J. Rare Dis. 10, 35 (2015).
53. Mascalzoni, D. et al. International Charter of principles for sharing bio-specimens and data. Eur. J. Hum. Genet. 23, 721–728 (2015).
54. McCormack, P. et al. ‘You should at least ask’. The expectations, hopes and fears of rare disease patients on large-scale data and biomaterial sharing for genomics research. Eur. J. Hum. Genet. 24, 1403–1408 (2016).
55. Beaulieu, C.L. et al. FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project. Am. J. Hum. Genet. 94, 809–817 (2014).
56. Precision Public Health Summit — Summit Report. https://cvp.ucsf.edu/PPHS-Summit-Report-For-Posting.pdf (2016) Accessed: 29 May 2017.
57. Rare Diseases International. Available from: http://www.rarediseasesinternational.org/ Accessed: 29 May 2017.
58. NGO Committee for Rare Diseases. Available from: http://www.ngocommitteerarediseases.org/ Accessed: 29 May 2017.
59. List of Medicinal Products for Rare Diseases in Europe, in Orphanet Report Series, Orphan Drugs Collection — April 2017. http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf Accessed 30 June 2017.
60. Orphanet — Orphan Drugs. Available from: http://www.orpha.net/consor/cgi-bin/Drugs_Search.php?lng=EN Accessed 30 June 2017.